Akseli Hemminki

University of Helsinki — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

77h-index28.0kcitations639works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(443), CAR-T cell therapy research(301), Cancer Research and Treatments(218), Viral Infectious Diseases and Gene Expression in Insects(169), RNA Interference and Gene Delivery(48)

Publications635 total

Increase in second primary lung cancers in a nation-wide cohort study from Sweden
Thorax·2026Open Access
Mutational landscape of lung adenocarcinoma in Czechia
Cancer Treatment and Research Communications·2026Open Access
Second Primary Lung Cancer Associated With Family History of Lung Cancer
Cancer Medicine·2025· 1 citedOpen Access
514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial
Regular and Young Investigator Award Abstracts·2025Open Access
Familial risks and incidence rates for childhood nervous system tumors in Sweden
EJC Paediatric Oncology·2025Open Access
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models
Cancer Immunology Immunotherapy·2025· 2 citedOpen Access
Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.
Journal of Clinical Oncology·2025· 1 cited
Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.
Journal of Clinical Oncology·2025
Oncolytic adenoviruses in platinum-resistant ovarian cancer: a new era in immunotherapy?
Expert Opinion on Biological Therapy·2025
Abstract 2035: Clinical-immunological correlates in platinum resistant or refractory ovarian cancer patients treated with chimeric oncolytic adenovirus encoding TNFa and IL-2 (TILT-123) in combination with pembrolizumab
Cancer Research·2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes
Cancer Gene Therapy·2025· 2 citedOpen Access
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma
Molecular Therapy Oncology·2025· 3 citedOpen Access
Sex specific familial risk in lung cancer through changing histologies in Sweden
International Journal of Cancer·2025· 2 citedOpen Access
Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention
Lung Cancer·2025· 1 cited
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma
Cell Reports Medicine·2025· 9 citedOpen Access
High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers
Hereditary Cancer in Clinical Practice·2025Open Access
Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers
Hereditary Cancer in Clinical Practice·2025· 3 citedOpen Access
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
Nature Communications·2025· 15 citedOpen Access
Safety And Immunological Activity Of A Oncolytic Adenovirus Expressing TNFa And IL-2 In Combination With Pembrolizumab In Platinum-Resistant Or Refractory Ovarian Cancer Patients
International Journal of Gynecological Cancer·2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
Journal for ImmunoTherapy of Cancer·2025· 5 citedOpen Access
page 1 of 32Next →

Frequent Co-authors

Anna Kanerva(17), Lauri A. Aaltonen(10), Lotta Kangasniemi(9), Vincenzo Cerullo(9), Heikki Järvinen(8), Reijo Salovaara(8), Sari Pesonen(7), Iulia Diaconu(7), Minna Oksanen(7), Leena Laasonen(7), Timo Joensuu(7), Ronald D. Alvarez(6), David T. Curiel(6), Sophie Escutenaire(6), Elina Haavisto(6), Kaarina Partanen(6), Saila K. Pesonen(6), Albert de la Chapelle(5), Jukka‐Pekka Mecklin(5), Jan Sundquist(5)